What is Recursion Pharmaceuticals Inc (RXRX) stock price today?

Recursion Pharmaceuticals Inc (RXRX) currently trades at $3.46 per share. The stock has a market capitalization of $1.80B and a P/E ratio of —x.

Is RXRX stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Recursion Pharmaceuticals Inc has a Smart Value Score of 36/100 (Grade D), resulting in a "Sell" investment rating. The Piotroski F-Score is 2/9 and Altman Z-Score is -0.86.

What is Recursion Pharmaceuticals Inc's revenue and earnings?

Recursion Pharmaceuticals Inc has trailing twelve-month (TTM) revenue of $74.68M with profit margins of 0.00%. Earnings per share (EPS) is $-1.44.

Is Recursion Pharmaceuticals Inc financially healthy?

Recursion Pharmaceuticals Inc's Piotroski F-Score is 2/9 (weak financial health). The Altman Z-Score of -0.86 places it in the distress.

RXRX

Recursion Pharmaceuticals Inc

NASDAQ: RXRX · HEALTHCARE · BIOTECHNOLOGY

$3.46

+4.85% today

Updated 2026-04-30

Market cap

$1.80B

P/E ratio

—

P/S ratio

24.12x

EPS (TTM)

$-1.44

Dividend yield

—

52W range

$3 – $7

Volume

13.8M

Market cap

$1.80B

P/E ratio

—

P/S ratio

24.12x

EPS (TTM)

$-1.44

Dividend yield

—

52W range

$3 – $7

Volume

13.8M

WallStSmart proprietary scores

out of 100

Grade: D

Sell

Investment rating

8.0

Growth

5.3

Quality

C+

2.5

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

-0.9

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$6.71

+93.93%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

2 Strong Buy1 Buy5 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Revenue growth 682.00% QoQ

Risks

- Piotroski 2/9 — weak financial health

- Altman Z -0.86 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-47.32M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM	2027 (E)
Revenue	$39.68M	$43.88M	$58.84M	$74.68M	$74.68M	$0.2B
Net income	$-239.42M	$-328.07M	$-463.66M	$-644.76M	$-108.12M	—
EPS	—	—	—	—	$-1.44	$-0.87
Free cash flow	$-120.88M	$-299.74M	$-372.87M	$-378.28M	$-47.32M	—
Profit margin	-603.36%	-747.71%	-788.02%	-863.35%	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
RXRX	$1.80B	36	8.0	2.5	5.0	5.3	—	Hold
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Recursion Pharmaceuticals Inc trades at $3.46. Our Smart Value Score of 36/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -0.86, it sits in the distress. TTM revenue stands at $74.68M.

Frequently asked questions

What is Recursion Pharmaceuticals Inc's stock price?

Recursion Pharmaceuticals Inc (RXRX) trades at $3.46.

Is Recursion Pharmaceuticals Inc overvalued?

Smart Value Score 36/100 (Grade D, Sell).

What is the price target of Recursion Pharmaceuticals Inc (RXRX)?

The analyst target price is $6.71, representing +93.9% upside from the current price of $3.46.

What is the future stock price of RXRX by 2030?

Our research-backed model estimates Recursion Pharmaceuticals Inc could reach $8.00 by 2030, based on analyst consensus, management guidance, and sector analysis.

What is Recursion Pharmaceuticals Inc's revenue?

TTM revenue is $74.68M.

Piotroski F-Score?

2/9 — weak financial health.

Altman Z-Score?

-0.86 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio24.12x

ROE-59.50%

Beta1.01

50D MA$3.42

200D MA$4.56

Shares out0.52B

Float0.51B

Short ratio—

Avg volume13.8M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

RXRX vs LLY →RXRX vs JNJ →RXRX vs ABBV →Stock screener →